146 related articles for article (PubMed ID: 15389512)
21. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.
Lintula S; Stenman J; Bjartell A; Nordling S; Stenman UH
Prostate; 2005 Jun; 63(4):324-9. PubMed ID: 15599939
[TBL] [Abstract][Full Text] [Related]
22. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen: what's new in 1997.
Pannek J; Partin AW
Oncology (Williston Park); 1997 Sep; 11(9):1273-8; discussion 1279-82. PubMed ID: 9306417
[TBL] [Abstract][Full Text] [Related]
24. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling.
Bridon DP; Dowell BL
Urology; 1995 May; 45(5):801-6. PubMed ID: 7538242
[TBL] [Abstract][Full Text] [Related]
25. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
26. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP
Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327
[TBL] [Abstract][Full Text] [Related]
27. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Saeid MS; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1999 May; 53(5):939-44. PubMed ID: 10223487
[TBL] [Abstract][Full Text] [Related]
28. PSA and other tissue kallikreins for prostate cancer detection.
Stephan C; Jung K; Lein M; Diamandis EP
Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
[TBL] [Abstract][Full Text] [Related]
29. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
[TBL] [Abstract][Full Text] [Related]
30. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
[TBL] [Abstract][Full Text] [Related]
31. Prostate-specific antigen and new related markers for prostate cancer.
Daher R; Beaini M
Clin Chem Lab Med; 1998 Sep; 36(9):671-81. PubMed ID: 9804390
[TBL] [Abstract][Full Text] [Related]
32. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract][Full Text] [Related]
33. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer.
Karazanashvili G; Abrahamsson PA
J Urol; 2003 Feb; 169(2):445-57. PubMed ID: 12544286
[TBL] [Abstract][Full Text] [Related]
34. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
[TBL] [Abstract][Full Text] [Related]
35. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.
Fisher TL; Nocera M; Willis RA; Turner MJ; Abdul Alim CS; Brown DM; Bourne PA; di Sant'Agnese PA; Messing EM; Lord EM; Frelinger JG
Prostate; 2002 May; 51(3):153-65. PubMed ID: 11967950
[TBL] [Abstract][Full Text] [Related]
36. Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
Siivola P; Pettersson K; Piironen T; Lövgren T; Lilja H; Bjartell A
Urology; 2000 Oct; 56(4):682-8. PubMed ID: 11018639
[TBL] [Abstract][Full Text] [Related]
37. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Steuber T; Niemela P; Haese A; Pettersson K; Erbersdobler A; Felix Chun KH; Graefen M; Kattan MW; Huland H; Lilja H
Prostate; 2005 Apr; 63(1):13-8. PubMed ID: 15378521
[TBL] [Abstract][Full Text] [Related]
38. Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn2+ and extracellular protease inhibitors.
Lövgren J; Airas K; Lilja H
Eur J Biochem; 1999 Jun; 262(3):781-9. PubMed ID: 10411640
[TBL] [Abstract][Full Text] [Related]
39. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels.
Charlesworth MC; Young CY; Klee GG; Saedi MS; Mikolajczyk SD; Finlay JA; Tindall DJ
Urology; 1997 Mar; 49(3):487-93. PubMed ID: 9123724
[TBL] [Abstract][Full Text] [Related]
40. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]